Erythropoietin: a candidate compound for neuroprotection in schizophrenia-Reference-Cited by-同舟云学术

Erythropoietin: a candidate compound for neuroprotection in schizophrenia

Published:2003-10-28 Issue:1 Volume:9 Page:42-54
ISSN:1359-4184
Container-title:Molecular Psychiatry
language:en
Short-container-title:Mol Psychiatry

Author:

Ehrenreich H,Degner D,Meller J,Brines M,Béhé M,Hasselblatt M,Woldt H,Falkai P,Knerlich F,Jacob S,von Ahsen N,Maier W,Brück W,Rüther E,Cerami A,Becker W,Sirén A-L

Publisher

Springer Science and Business Media LLC

Subject

Cellular and Molecular Neuroscience,Psychiatry and Mental health,Molecular Biology

Link

http://www.nature.com/articles/4001442.pdf

Reference58 articles.

1. Carlsson A . The current status of the dopamine hypothesis of schizophrenia. Neuropsychopharmacology 1988; 1: 179–186.

2. Andreasen NC, Olsen S . Negative v positive schizophrenia. Definition and validation. Arch Gen Psychiatry 1982; 39: 789–794.

3. Kremen WS, Seidman LJ, Faraone SV, Tsuang MT . Intelligence quotient and neuropsychological profiles in patients with schizophrenia and in normal volunteers. Biol Psychiatry 2001; 50: 453–462.

4. Haefner H, Hambrecht M, Loffler W, Munk-Jorgensen P, Riecher-Rossler A . Is schizophrenia a disorder of all ages? A comparison of first episodes and early course across the life-cycle. Psychol Med 1998; 28: 351–365.

5. Lieberman JA . Is schizophrenia a neurodegenerative disorder. A clinical and neurobiological perspective. Biol Psychiatry 1999; 46: 729–739.

Cited by 178 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Assessment of Innovative Pharmacological Targets in Schizophrenia;Current Treatment Options in Psychiatry;2024-07-13

2. Efficacy of erythropoietin as a neuroprotective agent in CKD-associated cognitive dysfunction: A literature systematic review;Pharmacological Research;2024-05

3. Effect of erythropoietin on cognitive side-effects of electroconvulsive therapy in depression: A randomized, double-blind, placebo-controlled trial;European Neuropsychopharmacology;2024-02

4. Pharmacological modulation of HIF-1 in the treatment of neuropsychiatric disorders;Journal of Neural Transmission;2023-09-22

5. Erythropoietin and Erythropoietin Receptor Levels and Their Diagnostic Values in Drug-naïve Patients with Generalized Anxiety Disorder;Clinical Psychopharmacology and Neuroscience;2023-05-30